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ABSTRACT – PURPOSE. To compare the 
flavonoid biomarker content (baicalin, baicalein 
and wogonin) of eleven commercial tinctures 
derived from Scutellaria lateriflora aerial parts 
(n=7) and Scutellaria baicalensis root (n=4). S. 
lateriflora tinctures are used by Western herbal 
practitioners to treat anxiety whereas S. 
baicalensis tinctures are used to treat 
inflammatory disease. METHODS. Baicalin and 
baicalein were purchased from Aldrich Chemical 
Co. and Wogonin was purchased from 
ChromaDex. The internal standard 
(4-hydroxybenzoic acid) was obtained from Acros 
Organics. The column used was a Luna C18, 5 μm 
(150 x 4.6 mm, Phenomenex) maintained at 
ambient room temperature. A HP1050 HPLC 
system was used, comprising a gradient pump 
with degasser, a variable wavelength UV detector 
set to 270 nm, and an autosampler. Gradient 
elution was performed using 0.1% formic acid 
(eluent A) and methanol (eluent B). The gradient 
elution initial conditions were 45% B with linear 
gradient to 60% from 2 to 10 min, followed by 
linear gradient to 70% B at 30 min, and then 
linear gradient to 99% B at 31 min, this 
proportion being maintained for 1 min. The 
mobile phase was then returned to initial 
conditions at 33 min and maintained until the end 
of the run at 35 min. The flow rate was 1 mL/min. 
The assay was validated for sensitivity, accuracy 
and reproducibility. RESULTS. The 
concentration range of biomarkers (baicalin, 
baicalein and wogonin) in commercial tinctures is 
reported for S. lateriflora (baicalin: 0-12.66 
mg/mL; baicalein: 0-0.63 mg/mL; wogonin: 
0-0.16 mg/mL) and for S. baicalensis (baicalin: 
0.12-10.61 mg/mL; baicalein: 0.52-5.88 mg/mL; 
wogonin: 0.08-1.61 mg/mL). CONCLUSION. 
The wide variability in biomarker concentrations 
between commercial tinctures has important 
implications for the manufacturers of commercial 
tinctures, for herbal practitioners in the choice of 
tinctures and not least for pharmacology and 
clinical researchers. 
 
INTRODUCTION 
 
The genus Scutellaria consists of over 350 
species worldwide and has been used by many 
cultures to treat a variety of medical conditions, 
including anxiety, nervous disorders, liver disease 
and cancers (1). Two species of particular interest 
are S. lateriflora Labiatae (American skullcap) 
and S. baicalensis Georgi (Chinese skullcap). The 
aerial parts of S. lateriflora, a native of North 
America, have a long tradition of use in Western 
herbal medicine as a relaxing nervine for sleep 
disorders and nervous conditions where stress and 
worry cause muscular tension. S. baicalensis is 
grown in China and Russia where root decoction 
has traditionally been used in Chinese medicine 
as a cancer treatment, remedy for inflammation, 
allergic disorders, hyperlipidemia and 
atherosclerosis (1). Western herbal practitioners 
use tinctures (hydroalcoholic solutions) as a 
common formulation due to ease of storage and 
dosage (2). These practitioners use tinctures of S. 
lateriflora aerial parts in the treatment of anxiety 
symptoms (including insomnia, anorexia nervosa 
and tension headache) and muscle spasms 
(including fibromyalgia, seizure disorders and 
mild Tourette’s syndrome) (1). A common daily 
dose of liquid extract (1:1 in 25% ethanol) is 
15-30 drops, equivalent to 2.0-4.0 mL per day and 
the daily dose of tincture (1:5 in 45% alcohol) is 
1-2 mL (3). 
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Although the flavonoids baicalin and baicalein 
(Figure 1) have previously been identified in S. 
lateriflora, anxiolytic activity of S. lateriflora was 
reported only for aqueous extracts, containing 
predominantly GABA amino acids, which were 
not quantified in this study (4).  
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Figure 1. Flavonoid biomarkers in Scutellaria: 1) 
Baicalein, 2) Wogonin and 3) Baicalin. 
 
 
 
The potential efficacy of standardised extracts of 
S. lateriflora as an anxiolytic in humans is 
claimed by a double blind, placebo-controlled 
clinical study of healthy adults (n=15 females and 
n=4 males, aged from 20-70 yrs) stating that 
skullcap reduced symptoms of anxiety and 
tension in a dose-dependent manner for 120 min 
after acute administration of 200 mg freeze-dried 
extract compared with control (5). Otherwise, 
there is scant data on constituents of S. lateriflora 
extracts and scant scientific evidence of anxiolytic 
activity. 
By comparison to S. lateriflora, the chemical 
constituents of S. baicalensis root are well- 
documented. S. baicalensis is one of the most 
widely used traditional herbal medicines in both 
Eastern and Western medicine by decoction 
(boiling plant material) or tinctures, respectively. 
Chinese medical herbalists use decoctions 
primarily in cancer treatment whereas Western 
medical herbalists use tinctures in 
anti-inflammatory, antibacterial, and anti-allergy 
therapy. A typical daily dose of S. baicalensis 
tincture is 15-30 drops, equivalent to 2.0-4.5 mL 
per day of 1:5 in 45% alcohol (3). Three 
important biomarkers isolated to date are the 
flavonoids, baicalin, baicalein, and wogonin (1). 
Baicalin has been reported as having various 
pharmacological properties including anti-tumor 
(6-8) anti-allergic (9-11), anti-inflammatory 
(12,13), antioxidant and radical scavenging 
activities (14-16). Baicalein presents the anti-HIV 
(17), anti-tumor (8), antioxidant and radical 
scavenging abilities (14-16). Wogonin possesses 
anti-tumor (8,18), anti-inflammatory (12), 
anti-hepatitis B virus (19), antioxidant and radical 
scavenging abilities (14).  
However, a concern for Western herbal 
practitioners is that commercial tinctures of both 
Scutellaria species vary widely in the 
drug-to-extract ratio (ranging from 1:1 to 1:5) and 
alcohol concentration (25 to 70%), depending on 
the manufacturer. Though S. lateriflora and S. 
baicalensis have demonstrable value as herbal 
therapy on the basis of continued traditional 
success, one unanswered question is the optimal 
choice of tincture composition with respect to 
drug-to-extract ratio and alcohol concentration. 
Whereas the quantitative and qualitative 
determination of a pharmaceutical component is 
critical in all stages of drug production, 
unfortunately in the herbal industry there is still 
no agreed uniform criterion for the production of 
tinctures. Previous work in our laboratory has 
shown wide variability in biomarker content 
(rosmarinic acid) for lemon balm (Melissa 
officinalis) (20). Thus, for the herbalist there is no 
guarantee or measure of either quality or efficacy 
from the products currently available. The main 
aims of this study are threefold. Firstly to develop 
and validate methods for the quantification of the 
three key flavonoid biomarkers (baicalin, 
baicalein, and wogonin) in commercial 
Scutellaria tinctures. Secondly to enable 
preliminary judgement to be made on the methods 
of commercial preparation of the herb likely to 
maximise the biomarker content of the end 
product. Thirdly to demonstrate to herbal 
practitioners, researchers, reviewers and 
manufacturers the extent of the variation in the 
biomarker content of commercially available 
herbal medicines and dietary supplements. This 
variation could help to explain the variable 
efficacy of herbal medicines used in clinical 
practice and also the variation in the reported 
activity of herbal medicines and dietary 
supplements in clinical trials and in assays of 
pharmacological activity (21,22).  
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MATERIALS AND METHODS  
 
Chemicals 
Standards of baicalin and baicalein were 
purchased from Aldrich Chemical Co. (Dorset, 
UK). Wogonin was purchased from ChromaDex, 
Irvine, California. The internal standard 
(4-hydroxybenzoic acid) was purchased from 
Acros Organics. (Leicestershire, UK). Formic 
Acid (Laboratory reagent grade) and methanol 
(HPLC grade) were purchased from Fisher 
Scientific Limited (Leicestershire, UK). Water 
was purified using a Purelab Option System from 
ELGA (Buckinghamshire, UK). 0.1% formic acid 
solution was prepared. 
 
Tinctures 
Sample tinctures of S. lateriflora and S. 
baicalensis were purchased anonymously from 
five companies, representing the range of 
products commonly used by herbal practitioners 
in the UK. These Test formulations from a 
particular manufacturer bore the same lot number 
and had an expiration date no earlier than 2 years 
from the date of purchase. The samples were 
randomly labeled SL1-7 (S. lateriflora) and 
SB1-4 (S. baicalensis), so their identity was not 
known until after the analysis was complete. 
 
Sample preparation for HPLC  
Eleven commercial tinctures (Samples SL1-7 and 
SB1-4) of Scutellaria (S. lateriflora and S. 
baicalensis) were used in this study. Comparison 
of baicalin, baicalein, and wogonin content was 
standardised on the basis of milligrams of baicalin, 
baicalein and wogonin per mL of tincture. 50 μL 
of tincture was added to 950 μL of methanol. 100 
μL of each solution were added to 100 μL of 
4-hydroxybenzoic acid (1000 μg/mL in methanol) 
solution. The resultant solutions were centrifuged 
at 13,000 min-1 for 5 min before injecting 10 μL 
on the HPLC system. Samples were freshly 
prepared daily. 
 
HPLC instrumentation 
The quantification of samples and the calibration 
curves were performed using a HP1050 series 
HPLC system comprising a gradient pump with 
degasser, a variable wavelength UV detector and 
an autosampler. The UV detector was set at 270 
nm and data was acquired using Totalchrom 
software (Massachusetts, USA) via a Perkin 
Elmer NCI902 data collector. The column used 
was a Luna C18, 5 μm (150 x 4.6 mm, 
Phenomenex) maintained at ambient room 
temperature. Gradient elution of the samples and 
standard were performed using 0.1% formic acid 
(eluent A) and methanol (eluent B). The gradient 
elution initial conditions were 45% of eluent B 
with linear gradient to 60% from 2 to 10 min, 
followed by linear gradient to 70% of eluent B at 
30 min, and then linear gradient to 99% of eluent 
B at 31 min, this proportion being maintained for 
1 min. The column was then returned to the initial 
condition at 33 min and maintained until the end 
of the run at 35 min. The flow rate was 1 mL/min. 
The sample injection volume was 10 μL: three 
injections were performed for each sample and 
standard. 
 
Quantitation of baicalin, baicalein and wogonin 
Baicalin, baicalein and wogonin calibration curves 
(n=6) were obtained by preparing stock solutions 
(1000 μg/mL) in methanol. Subsequent dilutions 
were made to give 500, 400, 300, 200, 100 and 50 
μg/mL. 100 μL of each solution were added to 100 
μL of 4-hydroxybenzoic acid, IS (1000 μg/mL in 
methanol) solution. After mixing, 10 μL of each 
final concentration were injected in triplicate. Stock 
solutions and dilutions were prepared fresh daily. 
The linearity of the calibration curves was 
determined (r2 > 0.998). The limit of detection 
(LOD) was calculated based on a signal-to-noise 
ratio (S/N: 3.3). The limit of quantitation (LOQ) 
was then calculated based on the signal-to-noise 
ratio (S/N: 10) using the lowest concentration in the 
calibration and the highest noise observed when 
injecting a blank (23). The intraday precision was 
calculated by comparing the ratio of the area of 
standard/area of internal standard obtained for 3 
injections of standards within the day. For the 
interday precision, the ratios of the area of 
standard/area of internal standard in the calibration 
curve for three days were summed and compared. 
All biomarker concentrations are quoted in μg/mL, 
mean ± standard deviation (SD), n = 3. 
 
RESULTS 
 
HPLC-UV determination of baicalin, baicalein 
and wogonin 
The HPLC-UV270nm chromatograms for samples 
SB1-4 and SL1-7 are illustrated in Figures 2 and 
3.
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Figure 2 HPLC-UV270nm chromatograms of commercial tinctures produced from S. lateriflora (SL1-7). Retention 
times of 4-hydroxybenzoic acid (IS), baicalin, baicalein and wogonin were observed at 3.6, 12.6, 16.6 and 21.9 min 
respectively 
Time (min) 
mV 
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Figure 3 HPLC-UV270nm chromatograms of commercial tinctures produced from S. baicalensis (SB1-4). Retention 
times of 4-hydroxybenzoic acid (IS), baicalin, baicalein and wogonin were observed at 3.6, 12.6, 16.6 and 21.9 min 
respectively. 
mV 
Time (min) 
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Retention times (tR) were 3.6, 12.6, 16.6 and 21.9 
min for 4-hydroxybenzoic acid, baicalin, 
baicalein and wogonin, respectively. The 
quantitation of baicalin, baicalein and wogonin 
was achieved using peak area ratios of baicalin, 
baicalein and wogonin to internal standard. The 
internal standard 4-hydroxybenzoic acid was 
chosen because previous injections of all the 
samples showed no major peaks at the observed tR 
of 4-hydroxybenzoic acid (3.6 min). The 
histograms in Figures 4 and 5 illustrate the 
resulting concentrations of baicalin, baicalein and 
wogonin among the 11 commercial preparations.  
 
The amount (µg/mL Mean ± SD) of baicalin, 
baicalein and wogonin in the commercial 
tinctures is given in Table 1. 
Linearity of the calibration curves was 
determined (r2 > 0.998) confirming the linearity 
of the analytical method. The intraday precision 
was calculated by comparing the ratio of the area 
of baicalin, baicalein and wogonin /area of 
internal standard (in triplicate) at the mid-point of 
the calibration curve (0.2 mg/mL) within the day 
and the resulting coefficient of variation obtained 
(% CV) was 0.03%, 0.17% and 0.10% 
respectively.
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Figure 4 Baicalin, baicalein and wogonin concentrations (μg/mL, mean ± SD, n= 3 measurements) in commercial S. 
lateriflora tinctures (SL1-7). 
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Figure 5 Baicalin, baicalein and wogonin concentrations (μg/mL, mean ± SD, n = 3 measurements)  in commercial S. 
baicalensis tinctures (SB1-4).  
J Pharm Pharmaceut Sci (www. cspsCanada.org) 11 (1): 77- 87, 2008 
 
 
 
 
83 
For the interday precision, the ratio of the area of 
baicalin, baicalein and wogonin/area of IS for the 
mid-point in the calibration curve (0.2 mg/ml) for 
three different days were added up and compared. 
The resulting % CV obtained was 0.36%, 0.62% 
and 0.71%, respectively. The accuracy of the 
method was calculated after nine injections of 
known concentration of baicalin, baicalein and 
wogonin (50 μg/mL) were carried out on three 
different days and were compared with the 
measured concentration (baicalin: 50 ± 4.61 
μg/mL; baicalein: 50 ± 4.34 μg/mL; wogonin: 50 
± 0.27 μg/mL). 
This together with the low standard deviation 
observed supported the accuracy of the analytical 
method. CVs smaller than ±15% of the measured 
value with respect to the known value reflect 
good accuracy of the method (23). The limit of 
detection (LOD) (S/N: 3.3) for baicalin, baicalein 
and wogonin using the developed method were 
2.20 ng/mL, 3.32 ng/mL and 4.34 ng/mL, 
respectively. The limit of quantification (LOQ) 
(S/N: 10) for baicalin, baicalein and wogonin 
using the developed method were 6.68 ng/mL, 
10.06 ng/mL and 13.16 ng/mL, respectively. 
 
DISCUSSION 
 
Analytical techniques for separation and analysis 
of Scutellaria baicalensis active components have 
been recently reviewed (24). Reversed-phase C18 
columns were most common, and mobile phases 
usually consisted of an acidic buffer to suppress 
ionisation of the acidic groups and an organic 
solvent (commonly methanol or acetonitrile). For 
example, 0.1% phosphoric acid/acetonitrile has 
been used in a 35 min gradient up to 90% 
acetonitrile (25). Another investigation originally 
used a phosphate buffer of pH 3.3 and methanol, 
but was improved with changing to acetic or 
formic acid at pH 2.5 – 3.0 and methanol (26). 
Among later investigations, 0.1% formic 
acid/acetonitrile was used with a gradient from 30 
to 85% acetonitrile in 16 min (27), or an isocratic 
mixture of methanol/0.1% formic acid (60:40 v/v) 
for LC-MS analysis (28). Others used 0.2% acetic 
acid/acetonitrile up to 60% acetonitrile over 55 
min and found that retention behaviour of 
flavonoids on a reversed phase column was 
remarkably affected by the pH of the mobile 
phase (29). 
In the present study, the importance of 
correct acid concentration emerged after initial 
chromatographic runs with 0.01% formic acid 
(measured pH 2.91)/methanol, with isocratic 
elution at 40% aqueous: 60% organic. While 
baicalein and wogonin eluted in that order from 
the column in line with previous reported results, 
baicalin eluted relatively later in the 
chromatogram with poor peak shape. In previous 
studies baicalin eluted early, and our tests varying 
the acidity of the mobile phase showed that if the 
formic acid concentration was raised to 0.1% 
(measured pH 2.62) baicalin eluted before the 
other two with good peak shape.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  The concentration (μg/ml) of baicalin, baicalein and wogonin present in 7 samples of 
Scutellaria lateriflora tinctures (SL1-7) and four samples of Scutellaria baicalensis tinctures (SB1-4). 
All values are mean ± SD (n=3) and are to 3 significant figures. The limits of detection (LOD) are 
0.002, 0.003 and 0.004 μg/mL respectively for baicalin, baicalein and wogonin. 
 
 
Baicalin  
 
Baicalein  
 
Wogonin  
 
SL1 <LOD 280 ± 1.3 <LOD 
SL2 180 ± 0.8 310 ± 1.5 119 ± 0.8 
SL3 <LOD <LOD <LOD 
SL4 199 ± 0.3 347 ± 1.0 157 ± 0.5 
SL5 268 ± 0.3 375 ± 0.8 97.5 ± 0.4 
SL6 <LOD 276 ± 1.5 <LOD 
SL7 12700 ± 60 629 ± 11 152 ± 0.5 
SB1 7270 ± 111 5880 ± 57 1610 ± 3 
SB2 177 ± 2.1 4430 ± 3 112 ± 2.9 
SB3 10600 ± 190 667 ± 2.8 262 ± 4.0 
SB4 117 ± 0.1 517 ± 1.0 80.0 ± 0.7 
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This acid concentration was therefore adopted for 
the reported HPLC protocol. Tests were carried 
out to optimize a gradient elution to achieve 
sufficient resolution between the selected 
biomarkers in the tincture products in order to 
obtain accurate quantitation while maintaining an 
acceptable gradient time. Few papers using 
HPLC-UV methods have included data regarding 
the lower limit of quantification (LLQ) (30-33). 
Our analytical method shows better sensitivity 
when compared to these other studies and has a 
comparable LLQ with LC-MS (29). 
Concerning Scutellaria liquid extracts and 
tinctures, herbal practitioners in the UK are thus 
faced with a wide range varying widely in the 
drug-to-solvent ratio (1:1 to 1:5) depending on the 
manufacturer (2). The concentration of alcohol 
used typically ranges from 70% down to 25%. 
Taken together, this variability in drug-to-extract 
ratio and the range of alcohol concentrations may 
partly explain the differential extraction of plant 
constituents, a common source of variability 
between commercial preparations. Variability 
within and between batches can result from 
different methods of cultivation, extraction, 
seasonal factors, time of harvesting, storage 
conditions and natural intraspecific variation in 
Scutellaria herb. A further compounding factor is 
the manufacturing process: cold maceration or 
percolation being two preferred methods (2). The 
quantitative data on the three biomarkers for S. 
lateriflora tinctures sourced from herbal suppliers 
used by UK herbal practitioners thus provide 
interesting results. According to the HPLC 
chromatograms (Figure 2), the products appear to 
fall into 3 distinct groups: SL7 is unique with 
higher concentrations of the biomarkers, 
particularly baicalin (12.66 mg/mL baicalin; 0.63 
mg/mL baicalein; 0.15 mg/mL wogonin) 
compared to SL1-6 (0 - 0.27 mg/mL baicalin; 0 - 
0.37 mg/mL baicalein; 0-0.20 mg/mL wogonin). 
It is notable that SL7 was the only product 
extracted in 45% ethanol compared to 25% for the 
other 6 products. Studies in our laboratory have 
confirmed that 45% ethanol extracts up to 5-fold 
more baicalein and 2-fold more baicalin than 25% 
ethanol for the same batch of herbal material. By 
contrast to SL7, the products SL2, 4 and 5 have 
similar chromatographic profiles not only in terms 
of the qualitative and quantitative data for the 
biomarkers, but also for other unidentified HPLC 
peaks present in similar proportions. Finally, the 
products SL1, 3 and 6 are distinguished by the 
lack of any appreciable biomarker content, but the 
presence of an unidentified HPLC peak at 11.9 
min. The HPLC chromatograms for S. baicalensis 
tinctures show similar variability in the biomarker 
content across the four products analysed (Figure 
3). Product SB4 appears to be lacking any 
appreciable biomarker content compared to 
SB1-SB3, which have similar qualitative profiles. 
The absence of baicalin is striking, as it is 
consistently the main biomarker identified in 
published chromatograms. It is also of note that 
the same manufacturer produced both SL7 and 
SB4, yet the SL7 product had higher 
concentrations of baicalin than competitors, 
whereas the SB4 product was notably lacking in 
any biomarker content by comparison with 
competitors.  
Importantly, although GMP regulations cover 
the manufacturing process they do not necessarily 
specify the quality or source of the starting plant 
material. This state of regulation has therefore led 
to the wide range in quality of Scutellaria 
products that face herbal practitioners in the UK 
due to plant material sourced within the UK and 
imported from countries including the Lebanon 
and the USA (S. lateriflora) and China (S. 
baicalensis). Implications of quality, seasonal 
variation and cost are obviously paramount to 
manufacturers and may even entail sourcing from 
different countries on a year-by-year basis, 
depending on availability of quality material. 
Interestingly, Han et al showed that 70% 
methanol extracts of S. baicalensis collected from 
six different regions of China gave virtually 
identical chromatograms by electrospray-MS 
analysis (29). Concerning the % ethanol used to 
prepare extracts, these products ranged from drug 
to solvent ratios of 1:1 to 1:5 and from 25% to 
70% ethanol. For these commercial products, no 
correlation between the concentration of ethanol 
used and concentration of biomarker was 
observed and further experiments using the same 
herbal material would be required to investigate 
the effects of % ethanol and drug to solvent ratios 
on efficiency of biomarker extraction. Clearly, the 
use of higher % ethanol, if proven to extract more 
of the biomarkers, would have cost implications 
for manufacturers. Further research on the 
efficacy of S. lateriflora as an anxiolytic and 
studies on the bioavailability of the biomarkers 
may be required to convince many manufacturers 
to use higher % ethanol extracts. Another 
important consideration is herbal practitioners' 
preference for using low alcohol extracts for 
young, elderly and hepatically-impaired patients.  
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The wide variability in biomarker content 
seen here for Scutellaria species reflects our 
previous study on the wide variability of 
biomarker content (rosmarinic acid) for tinctures 
made from both fresh and dried lemon balm 
(Melissa officinalis) (20). Two major concerns for 
manufacturers are the authentication of plant 
material and the shelf-life of tincture products. 
Commercial skullcap (S. lateriflora) has in the 
past been adulterated with Teucrium species, 
which has been associated with hepatotoxicity at 
certain doses, perhaps as a result of drug 
interactions (1,5). Although Gaffner et al reported 
teucrioside as a marker compound for Teucrium 
canadense L. and T. chamaedrys L. (34), there is 
as yet no HPLC-UV method to definitively 
authenticate S. lateriflora and much further 
research is needed. A further concern is that the 
shelf life of tincture products is under-researched. 
Gafner and Bergeron (35) provide an excellent 
review of the environmental factors affecting 
chemical stability of tinctures include pH, light 
and temperature. The presence of air in tincture 
products can lead to oxidation whilst the presence 
of metal ions mainly iron, copper and other 
transition metals, may cause hydrolysis and 
oxidation reactions with redox active molecules. 
Amber vials widely used to store tincture 
products contain significantly higher amounts of 
iron and titanium and may lead to leaching of 
metals leading to oxidation over a long storage 
period. Similarly, the presence of high levels of 
water has been shown in many studies to cause a 
more rapid decrease in important biomarker 
compounds. This could lead to differences in 
shelf-life between products containing 25% up to 
70% ethanol. In particular, Gafner and colleagues 
have reported the degradation of 
flavone-glucuronides by glucuronidases in fresh S. 
lateriflora extracts, where a combination of heat 
treatment and addition of antioxidants was 
required to stabilise extracts. Little systematic 
research has been done on the shelf-life of 
tincture products, and this parameter may be a 
source of variability amongst the products we 
tested. An important paper by Bilia and 
colleagues (36) reported a half life of only 3 
months for the purported bioactive silymarin 
complex in alcoholic tincture products of 
Milkthistle, as measured by LC-DAD and LC-MS. 
This has serious implications for storage and 
labeling of tincture products.  
Herbal practitioners rely to a large degree on 
anecdotal evidence in their prescribing of plant 
remedies due to a paucity of scientific research. 
However, the professional regulation of herbal 
practice is under review in the UK, and with the 
underlying principle of evidence-based practice 
informing primary healthcare, qualification of 
herbal practitioners arguably should involve an 
understanding of the pharmacological and 
pharmacodynamic basis of herbal medicine. 
There is therefore a pressing need to establish a 
scientific evidence base for the practice of herbal 
medicine to help herbalists to be more 
discriminatory in their choice of products. 
Additionally, in regard to quality, with currently 
no standardised production methods for the 
manufacture of tinctures used by herbalists there 
is no guarantee of quality or efficacy. One of the 
products tested here (SL7) would provide a daily 
dose of baicalin equivalent to 50 mg, compared to 
other tincture products that contain none. While it 
is not yet known whether baicalin is solely 
responsible for a putative anxiolytic activity, nor 
is the bioavailability in humans reported, this data 
is clearly important in deciding which products 
and what dose to use for further clinical research. 
There is thus an urgent need not only for a review 
by manufacturers of their production procedures 
for the herbs formulated as tinctures popularly 
used by herbal practitioners, but also for 
educating herbal practitioners to relate quality and 
efficacy. Clearly, for properly designed clinical 
trials to provide meaningful data, the method of 
preparation and quality of tincture products is 
critical in determining the efficacy of a given 
treatment. The data presented here provides 
valuable information as to which Scutellaria 
tincture products may be suitable for testing in 
vitro anxiolytic activity and for pilot clinical 
studies as an anxiolytic treatment. 
 
CONCLUSION 
 
Wide variability in the biomarker content of 
herbal preparations undermines the practice of 
herbal medicine. There is an urgent need for 
products to be labeled with accurate assessment 
of the content of agreed biomarkers. Authors, 
reviewers and editors responsible for reports of  
pharmacological and clinical activities of herbal 
products should ensure that the biomarker content 
of the product used is stated clearly. Where this 
ideal is not feasible full details of the source and 
the methods used in its preparation should be 
included for the benefit of future reviewers and 
meta-analysis. 
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